<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402142</url>
  </required_header>
  <id_info>
    <org_study_id>DCV-02/MANON07</org_study_id>
    <nct_id>NCT00402142</nct_id>
  </id_info>
  <brief_title>Dendritic Cell Vaccine in HIV-1 Infection</brief_title>
  <official_title>Phase II Study of Autologous Myeloid Dendritic Cells as a &quot;Cellular Adjuvant&quot; for a Therapeutic HIV-1 Vaccine in Early Stage HIV-1+ Patients (DCV-2).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To study the efficacy of a therapeutic HIV vaccine consisting of autologous myeloid
           dendritic cells pulsed ex vivo with high doses of inactivated autologous HIV-1, in HIV-1
           infected patients in a very early stages of the disease (CD4 &gt; 450 x 10 6 /L).

        2. To analyze the HIV-1 humoral and cellular immune responses induced by this immune-based
           therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our group has reported recently the first human trial of 4 therapeutic immunizations at
      six-week intervals with autologous monocyte-derived dendritic cells (MD-DC) loaded with
      heat-inactivated autologous HIV in 12 HIV infected patients who had been receiving highly
      active antiretroviral therapy (HAART) since early chronic infection. Autologous HIV was
      concentrated from plasma (1,500 ml) obtained by plasmapheresis after a 3-month HAART
      interruption (STOP1) performed 78 weeks before therapeutic immunizations, and HAART was
      discontinued again (STOP2) after therapeutic immunization. There was a decrease of set-point
      plasma viral load (PVL) &gt;= 0.5 log after 24 weeks off HAART in 4 out of 12 patients. In
      addition, we observed a significant lengthening in mean doubling time of PVL rebound (p=
      0.01), and significant decreases in the area under the curve of PVL rebound (p= 0.02) and in
      the mean peak PVL (p= 0.004) during the 12 weeks after STOP 2 compared with STOP1. This
      virological response was associated with a weak but significant increase in HIV-1 specific
      CD4 lymphoproliferative response, and with changes in HIV-1 specific CD8+ T-cell responses in
      peripheral blood and in lymphoid CTL cells after immunization. In lymphoid tissue, we also
      observed a trend towards a better control of HIV-1 replication coupled with an increase of
      CD4+ and CTL cells. No significant virological or immunological changes occurred in controls.
      We show that a therapeutic vaccine with autologous MD-DC pulsed with heat inactivated
      autologous HIV-1 is feasible, safe and well tolerated and elicited weak and transient
      cellular immune responses against HIV, associated with a partial and transient control of HIV
      replication in some patients.

      we hypothesized that a DC vaccine pulsed with higher amount of autologous virus obtained by
      culture could be more effective than the vaccine we used.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of steady state viremia (so-called viral set point) after 6-12 months after vaccination with viremia before HAART.</measure>
    <time_frame>6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion with evidence of HIV-specific CTL comparing end of immune-based therapy, and end of trial (week 48) with start of immune-based therapy.</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion with evidence of HIV-specific T-cell proliferative response comparing end of immune-based therapy, and end of trial (week 48) with start of immune-based therapy.</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion with evidence of HIV-specific neutralizing activity of serum comparing end of immune-based therapy, and end of trial (week 48) with start of immune-based therapy.</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 specific CTL responses in lymphoid tissue</measure>
    <time_frame>0 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DC Migration</measure>
    <time_frame>0 and 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load in semen and vaginal secretions</measure>
    <time_frame>0 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Pulsed dendritic cells untreated patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Untreated patients receiving a dendritic cell based vaccine pulsed with autologous heat iactivated virus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non pulsed dendritic cells untreated patients</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pulsed dendritic cell treated patient</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treated patients will be immunized with a dendritic cell vaccine pulsed with heat inactivated autologous virus immediately before art interruption</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pulsed dendritic cell in treated patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will be immunized with a dendritic cell vaccine pulsed with heat inactivted autologous virus immediately after interruption of art</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non pulsed dendritic cells</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dendritic cell vaccine</intervention_name>
    <description>107 DC subcutaneous 3 doses every 2 weeks</description>
    <arm_group_label>Pulsed dendritic cells untreated patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>non pulsed dendritic cell untreated patients</intervention_name>
    <description>107 DC subcutaneous 3 doses every 2 weeks</description>
    <arm_group_label>non pulsed dendritic cells untreated patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pulsed dendritic cell vaccine</intervention_name>
    <description>107 DC subcutaneous 3 doses every 2 weeks</description>
    <arm_group_label>pulsed dendritic cell treated patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>dendritic cell vaccine</intervention_name>
    <description>107 DC subcutaneous 3 doses every 2 weeks</description>
    <arm_group_label>pulsed dendritic cell in treated patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>non pulsed dendritic cell vaccine</intervention_name>
    <description>107 DC subcutaneous 3 doses every 2 weeks</description>
    <arm_group_label>non pulsed dendritic cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed HIV infection

          -  CD4 &gt; 450 x 10 6 /L

          -  baseline VL &gt;10,000 c/ml before any HAART

          -  Part I, patients off HAART at least during 6 months

          -  Part II, Patients on HAART with PVL &lt; 200 copies/ml at least during 6 months

          -  Written informed consent .

        Exclusion Criteria:

          -  Patients with failure to HAART

          -  Patients with B or C symptoms (CDC classification 1993).

          -  Age &lt; 18 years old.

          -  Pregnant or breastfeeding women

          -  Patients with baseline creatinin &gt; 2.5 mg/dl

          -  Patients with baseline GOT/GPT &gt; 250 UI/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Garc√≠a, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Cl√≠nic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Cl√≠nic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Garc√≠a F, Lejeune M, Climent N, Gil C, Alcam√≠ J, Morente V, Al√≥s L, Ruiz A, Setoain J, Fumero E, Castro P, L√≥pez A, Cruceta A, Piera C, Florence E, Pereira A, Libois A, Gonz√°lez N, Guil√° M, Caballero M, Lome√±a F, Joseph J, Mir√≥ JM, Pumarola T, Plana M, Gatell JM, Gallart T. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis. 2005 May 15;191(10):1680-5. Epub 2005 Apr 11.</citation>
    <PMID>15838795</PMID>
  </reference>
  <results_reference>
    <citation>Garc√≠a F, Climent N, Guardo AC, Gil C, Le√≥n A, Autran B, Lifson JD, Mart√≠nez-Picado J, Dalmau J, Clotet B, Gatell JM, Plana M, Gallart T; DCV2/MANON07-ORVACS Study Group. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med. 2013 Jan 2;5(166):166ra2. doi: 10.1126/scitranslmed.3004682.</citation>
    <PMID>23283367</PMID>
  </results_reference>
  <results_reference>
    <citation>Garc√≠a F, Climent N, Assoumou L, Gil C, Gonz√°lez N, Alcam√≠ J, Le√≥n A, Romeu J, Dalmau J, Mart√≠nez-Picado J, Lifson J, Autran B, Costagliola D, Clotet B, Gatell JM, Plana M, Gallart T; DCV2/MANON07- AIDS Vaccine Research Objective Study Group. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis. 2011 Feb 15;203(4):473-8. doi: 10.1093/infdis/jiq077. Epub 2011 Jan 13.</citation>
    <PMID>21233310</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2006</study_first_submitted>
  <study_first_submitted_qc>November 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <last_update_submitted>February 25, 2014</last_update_submitted>
  <last_update_submitted_qc>February 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Felipe Garcia</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>HIV Infection</keyword>
  <keyword>Dendritic cell vaccine</keyword>
  <keyword>Autologous virus</keyword>
  <keyword>Heat inactivated</keyword>
  <keyword>HIV Therapeutic Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

